within Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DC04_Ibudilast;

model Ibudilast
  extends Pharmacolibrary.Drugs.ATC.R.R03DC04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R03DC04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ibudilast is a non-selective phosphodiesterase inhibitor and glial cell modulator used for its neuroprotective and anti-inflammatory properties. It has been used mainly in Japan for the treatment of asthma and post-stroke dizziness, and has also been investigated for use in neuropathic pain, multiple sclerosis, and substance use disorders. While approved in Japan, it is not approved by the FDA or EMA for clinical use in Europe or the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for typical adult, oral administration. No clinical PK publications with full compartmental PK parameter sets found.</p><h4>References</h4><ol><li><p>Sanftner, LM, et al., &amp; Johnson, KW (2009). Cross-species comparisons of the pharmacokinetics of ibudilast. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 39(12) 964–977. DOI:<a href=&quot;https://doi.org/10.3109/00498250903254340&quot;>10.3109/00498250903254340</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19925385/&quot;>https://pubmed.ncbi.nlm.nih.gov/19925385</a></p></li><li><p>Rolan, P, et al., &amp; Johnson, KW (2008). Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. <i>British journal of clinical pharmacology</i> 66(6) 792–801. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2008.03270.x&quot;>10.1111/j.1365-2125.2008.03270.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19032723/&quot;>https://pubmed.ncbi.nlm.nih.gov/19032723</a></p></li><li><p>Yoon, H, et al., &amp; Lee, YB (2010). Determination of ibudilast in human serum by high-performance liquid chromatography for pharmacokinetic study. <i>Biomedical chromatography : BMC</i> 24(3) 324–328. DOI:<a href=&quot;https://doi.org/10.1002/bmc.1293&quot;>10.1002/bmc.1293</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19629961/&quot;>https://pubmed.ncbi.nlm.nih.gov/19629961</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ibudilast;
